April 2022 - Page 18 of 28

WednesdayApr 13, 2022 11:32 am

QualityStocksNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced positive preclinical data from a pharmacokinetic study evaluating its proprietary deuterated dimethyltryptamine (“DMT”) molecule, CYB004, delivered via inhalation. According to the announcement, inhaled CYB004 demonstrated significant advantages over both intravenous and inhaled DMT, including longer duration of action and improved bioavailability. The study also demonstrated that inhaled CYB004 showed a similar dose profile and onset of effect to IV DMT. “In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues. However, known side…

WednesdayApr 13, 2022 11:18 am

QualityStocksNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Marks Historic Week with Shipments of Uranium, Vanadium, REE

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, hit a critical mineral “trifecta” this month, making commercial shipments of uranium, vanadium and advanced rare earth materials — all in a single week. According to the announcement, the company shipped natural uranium concentrates (“U308”) to the Metropolis Works uranium conversion facility in Metropolis, Illinois; vanadium pentoxide (“V205”) to the Bear Metallurgical Company in Butler, Pennsylvania; and high-purity mixed rare earth element (“REE”) carbonate to the Neo Performance Materials facility in Estonia. “I believe the week of April 4, 2022, will go down as one of the most important weeks in…

WednesdayApr 13, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Introduces FDA-Approved SPRAVATO(R) Nasal Spray at KWC Clinics in a Move to Make Mental health Treatment Effective and Affordable

Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1 SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressant Its introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through its wholly-owned subsidiary, Delic Labs, has remained committed to expanding its ability to research novel compounds and developing intellectual property (“IP”) for future commercialization of novel psychedelic compounds for medical use. So far,…

WednesdayApr 13, 2022 9:30 am

O’Cannabiz Conference Expo & Awards Offering A Confluence Of Cannabis Industries

Cannabis enthusiasts, traders, cultivators and allied industries are invited to attend the O’Cannabis Expo & Awards from June 1-3, 2022 In Toronto, Canada. After the last year’s rescheduling, the O’Cannabis Conference is back this year for a physical 3-day event. The team is grateful to the exhibitors, sponsors, partners as well as pre-purchased ticket holders for their patience and trust. The event venue is the International Centre Hall #5, Toronto, Canada, a hub of business and consumer exhibitions in Canada. O’Cannabiz is a leading company engaged in organizing national high-profile events, to foster global connections between business houses and the…

WednesdayApr 13, 2022 9:15 am

GreenBox POS (NASDAQ: GBOX) Releases Fourth Quarter and Full Year 2021 Results

On March 31, GreenBox POS released the financial results for the three months (“Q4 FY 2021”) and full year (“FY2021”) ended December 31, 2021 Company achieved record revenue in 2021 of $26.3 million, an increase of $17.8 million or 208.6% from $8.5 million in 2020 The Q4 FY2021 results build on Q3 2021 figures in which the company reported year-over-year growth in both transaction volume and revenues The financial figures were accompanied by a corporate update and expected prospects for 2022. On Thursday, March 31, at 4.30 PM Eastern, investors, stakeholders, and the general public heard about the progress that…

WednesdayApr 13, 2022 9:15 am

InnerScope Hearing Technologies Inc. (INND) Ends 2021 on Right Foot, Set for a Dominant 2022

Over 31 million Americans have hearing loss but don’t utilize a hearing aid, primarily due to prohibitively high costs In the last 5 years, U.S. Presidents and Congress has demonstrated a strong commitment to making hearing aids affordable to all, including pressure on the FDA to complete changes now InnerScope has aggressively grown its business model through two key acquisitions and new sales channels that should lend to significant revenue growth as new regulations are put in place More than 38 million Americans have some degree of hearing loss. Sadly, due mostly to prohibitively high costs, only about 20% of…

WednesdayApr 13, 2022 9:00 am

European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug

Novel brain cancer drug developer CNS Pharmaceuticals is developing a proprietary pharmaceutical candidate called Berubicin for the treatment of glioblastoma multiforme (“GBM”) CNS has received Fast Track designation for Berubicin, which will allow the company more frequent communications with the FDA CNS has initiated a global potentially pivotal clinical trial to evaluate Berubicin in treating GBM and began dosing patients at sites scattered across several states last year, with numerous additional sites preparing to enroll patients in the coming months CNS is now reporting approval from regulatory authorities in Switzerland and France to proceed with recruiting patients there The study…

TuesdayApr 12, 2022 2:39 pm

QualityStocksNewsBreaks – RYAH Group Inc. (CSE: RYAH) Names New Director, CEO

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, has announced that its board of directors has nominated Dr. David R. Richards, PhD, FIoD, FRSA, CPsych, as a new director and the company’s chief executive officer. Richards comes to the new positions with impressive experience, including serving in leadership roles at Nortel Networks' GM Global Data; GM Global Supercarriers; GM UK Switching; and Global ThinkQuest Champion at Oracle's Education Foundation. He has served as CEO of Ellis Jones Solicitors, executive director of…

TuesdayApr 12, 2022 1:03 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a minimum 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study to compare Lexaria's DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. Lexaria hopes to evidence that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to brands currently on the market. The study’s primary objective is data collection…

Site Search

Company Search

Month: April 2022